Sclerostin antibody stimulates bone regeneration after experimental periodontitis by Taut, Andrei D et al.
Sclerostin Antibody Stimulates Bone Regeneration After
Experimental Periodontitis
Andrei D Taut,1 Qiming Jin,2 Jong‐Hyuk Chung,1,3 Pablo Galindo‐Moreno,1,4 Erica S Yi,1
James V Sugai,1 Hua Z Ke,5 Min Liu,5 and William V Giannobile1,6
1Department of Periodontics and Oral Medicine, School of Dentistry, University of Michigan, Ann Arbor, MI, USA
2Department of Cariology, Restorative Sciences, and Endodontics, School of Dentistry, University of Michigan, Ann Arbor, MI, USA
3Department of Periodontology, School of Dentistry, Kyung Hee University, Seoul, South Korea
4Department of Oral Surgery and Implant Dentistry, University of Granada, Granada, Spain
5Department of Metabolic Disorders, Amgen Inc., Thousand Oaks, CA, USA
6Department of Biomedical Engineering, College of Engineering, University of Michigan, Ann Arbor, MI, USA
ABSTRACT
The reconstruction of large osseous defects due to periodontitis is a challenge in regenerative therapy. Sclerostin, secreted by osteocytes,
is a key physiological inhibitor of osteogenesis. Pharmacologic inhibition of sclerostin using sclerostin‐neutralizingmonoclonal antibody
(Scl‐Ab) thus increases bone formation, bone mass and bone strength in models of osteopenia and fracture repair. This study assessed
the therapeutic potential of Scl‐Ab to stimulate alveolar bone regeneration following experimental periodontitis (EP). Ligature‐induced
EP was induced in rats to generate localized alveolar bone defects. Following 4 weeks of disease induction, Scl‐Ab (þEP) or vehicle (þ/
EP) were systemically delivered, twice weekly for up to 6 wks to determine the ability of Scl‐Ab to regenerate bone around tooth‐
supporting osseous defects. 3 and 6 wks after the initiation of Scl‐Ab or vehicle treatment, femur andmaxillary jawbones were harvested
for histology, histomorphometry, and micro‐computed tomography (micro‐CT) of linear alveolar bone loss (ABL) and volumetric
measures of bone support, including bone volume fraction (BVF) and tissuemineral density (TMD). Serumwas analyzed to examine bone
turnover markers during disease and regenerative therapy. Vehicleþ EP animals exhibited maxillary bone loss (BVF, TMD and ABL) at
ligature removal and thereafter. 6 weeks of Scl‐Ab signiﬁcantly improved maxillary bone healing, as measured by BVF, TMD and ABL,
when compared to vehicleþ EP. After 6 weeks of treatment, BVF and TMD values in the Scl‐Abþ EP group were similar to those of
healthy controls. Serum analysis demonstrated higher levels of bone formationmarkers osteocalcin and PINP in Scl‐Ab treatment groups.
Scl‐Ab restored alveolar bonemass following experimental periodontitis. These ﬁndings warrant further exploration of Scl‐Ab therapy in
this and other oral bone defect disease scenarios. © 2013 American Society for Bone and Mineral Research.
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Introduction
Periodontal disease is a destructive disease that targets tooth‐supporting structures of the dentition through complex and
multifactorial pathogenic processes. They are initiated by an
interaction between bacterial components of tooth‐related
bioﬁlms and host response mechanisms.(1) Although gingivitis
represents the reversible inﬂammatory reaction to bioﬁlms,
periodontitis is the nonreversible destructive stage of a
persistent bacterial infection.(2) Left untreated, periodontitis
results in soft tissue destruction and progressive bone destruc-
tion, leading to tooth mobility and subsequent tooth loss.(3)
Various treatment procedures have been widely used for
periodontal regeneration therapy. However, reconstruction of
large osseous defects resulting from periodontal disease remains
a challenge, and procedures such as bone grafts and guided
bone regeneration remain unpredictable in their ability to
consistently regenerate bone.(4) Studies on cellular and molecu-
lar mechanisms of Wnt and BMP signaling on bone homeostasis
have suggested that the use of Wnt signal‐enhancing agents
may be a promising alternative therapy to prevent bone loss and
regenerate periodontal supporting tissues.(5)
Sclerostin, a secreted glycoprotein, is the product of the SOST
gene. Sclerostin, produced and secreted primarily by osteocytes,
has been shown to be a negative regulator of osteoblast
differentiation/function and an inhibitor of bone formation.
Although the exact mechanism by which sclerostin inhibits
bone formation has not yet been fully identiﬁed, studies have
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demonstrated that sclerostin may act through LRP5/6 to inhibit
Wnt/beta‐catenin signaling, impairing osteoblast differentiation
and function.(6,7) As such, inhibition of sclerostin could then lead
to an increase in Wnt/beta‐catenin signaling, thereby increasing
bone formation.
Human genetics show that patients with loss‐of‐function
mutations in the SOST gene have high bone mass and density,
including in their jawbones.(8–10) SOST null mice have increased
bone formation, bone mass, and bone strength.(11) Sclerostin
deﬁciency in human sclerosteosis, together with the high bone
mass phenotype of SOST null mice, suggest that sclerostin
inhibition may be a viable approach for developing novel bone
anabolic agents for treatment of bone disorders, including
alveolar bone loss. Amurine anti‐sclerostin monoclonal antibody
that neutralizes sclerostin (Scl‐Ab) has been developed,(12) and
has been shown to restore bone formation, bonemass, and bone
strength in a rat model of postmenopausal osteoporosis.(13)
Furthermore, rat and nonhuman primate models show that
systemic Scl‐Ab administration can locally increase bone
formation to enhance fracture healing.(14) Clinical studies
indicate that Scl‐Ab administration to healthy men and
postmenopausal women increased bone formation markers
and bone mineral density (BMD), suggesting therapeutic
potential for Scl‐Ab in osteoporosis and other bone disorders
that might beneﬁt from increased bone formation.(15)
The current study provides one of the ﬁrst tests of the
hypothesis that Scl‐Ab administration can have favorable
impacts on disease‐affected craniofacial tissues. This study
aimed to determine the role of a neutralizing anti‐sclerostin
antibody (Scl‐Ab), as a bone anabolic agent, to regenerate
alveolar bone after experimental periodontitis.
Materials and Methods
Scl‐Ab administration in healthy (intact) Sprague‐Dawley
rats
All animal procedures were performed under guidelines
approved by the University of Michigan Unit for Laboratory
Animal Medicine (ULAM), University Committee on Use and Care
of Animals (UCUCA), and compliant with Animals Research:
Reporting In Vivo Experiments (ARRIVE) guidelines. To examine
the effect of sclerostin blockade in alveolar bone, healthy (intact)
rats were treated with either vehicle (n¼ 10) or Scl‐Ab (ratized
monoclonal Scl‐Ab III, Amgen Inc., Thousand Oaks, CA, USA;
n¼ 8)(5) via subcutaneous injections into the dorsa of 9‐week‐old
adult male Sprague‐Dawley rats (Charles River Laboratories
International, Inc., Wilmington, MA, USA), twice weekly for 2 and
4 weeks. Phosphate‐buffered saline (1X PBS; Life Technologies,
Grand Island, NY, USA) served as the vehicle control in all
studies. Maxillary alveolar bone specimens including ﬁrst,
second, and third molars were collected for mCT scanning
and volumetric analysis (described below). Femora were
harvested to assess the systemic bone anabolic effects of
Scl‐Ab after 4 weeks. Serum was also collected at 2 and 4 weeks
to evaluate systemic biochemical markers of bone formation and
resorption.
Experimental periodontal disease (EP) model
After a 1‐week acclimation period, adult male Sprague‐Dawley
rats (approximate weight 250 to 300 g, aged 9 to 10 weeks in
regenerative study) were anesthetized using isoﬂurane inhala-
tion (Charles River Laboratories International, Inc.). Silk sutures
(3/0) were placed unilaterally into the gingival sulci of the left
maxillary ﬁrst and second molar teeth to induce experimental
periodontitis (EP) through: 1) activation of inﬂammatory
responses against the increased presence of microbial bioﬁlm;
and 2) physical irritation and destruction of alveolar bone as a
result of subgingival placement of suture material.(16) Sutures
were displaced apically into the gingival sulci twice weekly to
ensure a subgingival position and were replaced as necessary.
Regeneration of alveolar bone after experimental
periodontitis
Experimental periodontitis was induced for a period of 4 weeks.
Intact, healthy controls were not ligated and served as
controls. Ligatures were removed at the end of the experimental
periodontitis phase before initiating Scl‐Ab treatment. To
investigate its regenerative potential, Scl‐Ab or its vehicle control
was administered subcutaneously at a dose of 25mg/kg,
twice weekly for therapeutic periods of 3 and 6 weeks (n¼ 7
and n¼ 8, respectively) after a 4‐week phase of experimental
periodontitis (Fig. 1A), whereas intact, healthy controls were
treated with 1X PBS (3 weeks, n¼ 9; 6 weeks, n¼ 8). In other EP
animals, Scl‐Ab was administered locally, twice weekly for 3 and
6 weeks (n¼ 10 and n¼ 8, respectively), into three palatal gingival
tissue sites: between the left maxillary ﬁrst and second molars and
near the base of the interproximal gingival papillae (5mL of a
35.6mg/mL solution per site, totaling 15mL per animal per
treatment session) as previously described, with 1X PBS serving as
the control (3 weeks, n¼ 10; 6 weeks, n¼ 9).(17)
Micro‐computed tomography scanning and bone
analysis
Maxillary bone specimens—including ﬁrst, second, and third
molars—were collected at the designated end points, placed in
10% neutral‐buffered formalin for 2 days, and transferred to 70%
ethanol (EtOH) for mCT scanning. Fixed, undecalciﬁed maxillae
were scanned using a cone beam mCT system (GE HealthCare
BioSciences, Model Pxs5‐928EA, GE Healthcare, London, ON,
Canada) at the University of Michigan Orthopaedic Research
Imaging Laboratory. The X‐ray generator was operated at an
accelerated potential of 80 kV with a beam current of 80mA and
the X‐ray source 2D detector operated with a shutter speed of
1100ms to produce images with a voxel size of 18 18 18mm.
Scans were reconstructed and three‐dimensional (3D) digitized
images generated for each specimen. Using GEMS MicroView
software (eXplore MicroView v.2.1.2, Analysis Plus, GE Health-
care), each reconstructed image was rotated into a standardized
orientation, and a region of interest (ROI) for each specimen was
created as previously described with minor modiﬁcations.(17)
Brieﬂy, for volumetric analysis of the maxillary tooth‐supporting
alveolar bone, the furcation origin of the ﬁrst maxillary molar,
apices of the mesial root of the ﬁrst maxillary molar/distal root of
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the third maxillary molar, and the mesial roots of the ﬁrst molar
and distal roots of the second molar were used as landmarks
for quantifying alveolar bone loss and regeneration within a
reproducible region (Fig. 1D–E). Using the average Hounsﬁeld
Units (HU) grayscale threshold value for all of the samples,
a single, calibrated examiner (AT) volumetrically quantiﬁed the
alveolar bone surrounding ﬁrst and second maxillary molars
(Fig. 1F), including bone volume fraction (BVF) and tissue mineral
density in mg/mm3 (TMD). Additionally, a single, calibrated
examiner (EY) linearly measured linear alveolar bone loss (ABL) in
millimeters, according to a previously described protocol.(18) ABL
is used clinically to quantify the integrity of structural support
around a tooth. High ABL values indicate bone loss, whereas low
ABL values are correlated with healthy bone levels. Brieﬂy, ABL
was measured as the linear distance between the cementoena-
mel junction and alveolar bone crest at ﬁve sites (mesial [M],
mesiolingual [ML], mesiobuccal [MB], distolingual [DL], and
distobuccal [DB]) for M1 and at four sites (ML, MB, DL, and DB) for
M2 as shown in Fig. 1B, C. ABL data were presented as the overall
average of the linear measures for M1 and M2.
Bone‐specific serum biomarkers
Serumwas obtained from blood collected by cardiac puncture at
the designated study end points. Serum osteocalcin (OCN) was
measured using the rat Osteocalcin Single‐plex LINCOplex Kit
(RBN‐31K‐1OC, Millipore, St. Charles, MO, USA). Serum procolla-
gen type 1 amino‐terminal propeptide (P1NP) and tartrate‐
resistant acid phosphatase 5b (TRACP 5b) were detected using
rat ELISA kits (AC‐33F1, SB‐TR102, IDS, Fountain Hills, AZ, USA).
Histology and descriptive bone histomorphometry
Rats were euthanized in a CO2 chamber at the speciﬁed time
points, and maxillary specimens (containing ﬁrst/second/third
maxillary molars and surrounding alveolar bone) were harvested
and ﬁxed in 10% neutral‐buffered formalin for 48 hours. After
mCT analysis, specimens were decalciﬁed with 10% EDTA
disodium salt for 3 weeks, embedded in parafﬁn, and cut into
5‐mm‐thick serial sagittal sections of the maxillary ﬁrst, second,
and third molars. Sections were stained with hematoxylin
and eosin for descriptive analysis. Remaining sections were
deparafﬁnized and immunostained for detection/localization of
SOST and CathK (goat anti‐mouse SOST antibody, R&D Systems,
catalog no. AF1589; rabbit polyclonal anti‐cathepsin K, Amgen,
Thousand Oaks, CA, USA). Histological and immunohistochemi-
cal images were captured with a Nikon Eclipse 50i microscope
(Nikon Inc., Melville, NY, USA) and Nikon Digital Sight DS U1
camera (Nikon Inc.). The fraction of the bone surface covered by
osteoclasts on the interproximal bone between M1 and M2 was
calculated using NIS Elements Basic Research software (Nikon
Inc.).
Fig. 1. Study timeline and three‐dimensional measures for analysis of tooth‐supporting alveolar bone. (A) Regenerative study timeline began with
4 weeks of experimental periodontitis, followed by ligature removal and 3 and 6 weeks of subcutaneous and local Scl‐Ab administration. Lingual (B) and
buccal (C) 3D views of maxilla at the site of ligature placement. Linear alveolar bone loss (ABL), or the linear distance (orange line) between
the cementoenamel junction (CEJ; yellow‐dashed line) and alveolar bone crest (green line), was measured along ﬁve roots for M1 and four roots for M2.
(D) Anatomical landmarks of M1 and M2 were used to create a three‐dimensional ROI (yellow box). (E) M1, M2, and M3 were digitally removed and tooth‐
supporting bone within the disease region was isolated for volumetric quantiﬁcation (F).
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Fluorescent calcein labeling
To assess the mineral deposition rate of alveolar bone during the
regenerative phase, rats were given two subcutaneous injections
of calcein, 9 and 2 days before euthanasia according to a
standard protocol.(19) Mandibulae from each animal (n¼ 2) were
harvested, dehydrated, and embedded undecalciﬁed in meth-
ylmethacrylate for sectioning. Image capture and descriptive
histomorphometry were performed on two consecutive non-
stained 4‐mm sections.
Femur bone mineral density
To assess systemic bone‐building effects of Scl‐Ab, femura from
each animal were harvested at euthanization, ﬁxed in 10%
phosphate‐buffered formalin for 48 hours at 4°C, and stored in
70% EtOH. Areal BMD of left femur was determined ex vivo by
dual‐energy X‐ray absorptiometry (DXA; Hologic QDR 4500a,
Bedford, MA, USA). The DXAmachinewas calibrated according to
the manufacturer’s instructions.
Prevention of alveolar bone destruction during
experimental periodontitis
We also conducted a study to examine the potential for Scl‐Ab to
prevent the progression of alveolar bone destruction with EP, by
initiating Scl‐Ab treatment just before the placement of ligatures.
Sprague‐Dawley rats with EP were assigned to receive either
vehicle or Scl‐Ab and intact animals served as the control. Three
days before EP induction, a single‐dose Scl‐Ab (25mg/kg) was
administered via subcutaneous injection. From then onward,
Scl‐Ab and vehicle injections continued twice weekly for 2 and
4 weeks, concurrently with EP, starting on the day of ligature
placement. Maxillary alveolar bone specimens were collected for
mCT scanning and volumetric analysis (as described above).
Statistical analysis
Statistical analyses were performed using GraphPad Prism
software. Data were pooled by experimental group, and the
mean and standard deviation (SD) were calculated. One‐way
analysis of variance (ANOVA) followed by Newman‐Keuls post
hoc tests were performed for measuring statistically signiﬁcant
differences between groups for serum biomarker levels,
volumetric and linear bone levels, and osteoclast number. A
p value less than 0.05 was considered to be statistically
signiﬁcant. Statistical analysis was carried out in consultation
with the Center for Statistical Consultation and Research (CSCAR)
at the University of Michigan.
Results
Pharmacological inhibition of sclerostin in healthy
alveolar bone
A study was conducted to ﬁrst address whether Scl‐Ab had bone
anabolic effects on healthy, intact maxillary alveolar bone in rats.
The mCT data in Fig. 2A indicate that Scl‐Ab signiﬁcantly
increased maxillary BVF and TMD in intact healthy rats lacking
ligatures compared with vehicle treatment at 2 weeks (BVF,
p¼ 0.001; TMD, p¼ 0.003) and at 4 weeks (BVF, p¼ 0.001; TMD,
p¼ 0.010). DXA scanning and analysis of animal long bone was
performed to conﬁrm the systemic treatment effects of Scl‐Ab in
other skeletal sites. As expected, the areal femoral BMD, serum
P1NP, and OCN were increased (p< 0.0001, p¼ 0.0003, and
p¼ 0.058, respectively) in Scl‐Ab–treated intact animals com-
pared with the vehicle control group at 4 weeks (Fig. 2B, C),
consistent with the systemic bone anabolic effects. This result
provided the rationale for examining the therapeutic potential of
Scl‐Ab in periodontal disease‐related bone loss. Such conditions
were then mimicked in a separate study by initiating Scl‐Ab
treatment after ligature‐induced inﬂammation and maxillary
bone loss had already occurred.
Pharmacological inhibition of sclerostin in established
alveolar bone loss
Four weeks of ligature‐induced EP led to signiﬁcant reductions in
alveolar bone volume and density aroundmaxillary ﬁrst (M1) and
second (M2) molars compared with the intact control group
(week 0/BL data, Fig. 3A, B). After ligature removal, natural bone
healing led to a rebound in BVF and TMD in vehicle‐treated rats
lasting 3 weeks. However, after 3 weeks, alveolar bone healing
plateaued in rats receiving vehicle treatment (week 3 data,
Fig. 3A, B). Three weeks after commencement of systemic Scl‐Ab
therapy, Scl‐Ab–treated animals exhibited a trend toward
increased BVF (p< 0.05) and TMD (p< 0.05) compared with
the vehicle group. Most notably, systemic Scl‐Ab therapy
reversed ligature‐induced bone loss after the 6‐week treatment
period, with no differences evident between BVF (p¼ 0.3378)
and TMD (p¼ 0.4196) of EP animals treated with Scl‐Ab and the
intact animal group (week 6 data, Fig. 3A, B; Fig. 4B). Furthermore,
BVF and TMD of both Scl‐Ab and intact animal groups were
signiﬁcantly greater compared with the vehicle treatment group
after 6 weeks of Scl‐Ab treatment (Fig. 4). In contrast, local
injection of Scl‐Ab after experimental periodontitis exhibited a
limited regenerative effect on volumetric alveolar bone healing,
as indicated by mCT analysis (Supplemental Fig. S1).
Systemic Scl‐Ab administration showed no effects on the EP‐
related linear alveolar bone loss (ABL) at 3 weeks (p> 0.05),
whereas it led to a modest but statistically signiﬁcant improve-
ment in linear ABL from EP (p< 0.05) at 6 weeks when compared
with vehicle treatment (Fig. 3C). Site‐speciﬁc analysis revealed
that ABL gain occurred primarily on the buccal regions of M1 and
M2 (data not shown).
DXA scanning of femurs was performed to evaluate systemic
(post‐cranial) skeletal responses to Scl‐Ab. Femur BMD was
signiﬁcantly increased after 3 weeks (p< 0.001) and 6 weeks
(p< 0.001) in Scl‐Ab–treated animals compared with both intact
and vehicle‐treated EP groups (Fig. 5A).
Regeneration mode: bone‐formation biomarkers
During early healing, serum OCN concentration was signiﬁcantly
higher in animals treated with Scl‐Ab compared with intact
(p¼ 0.0019) and vehicle (p¼ 0.0001) groups after 3 weeks of
treatment (Fig. 5B). At 6 weeks post‐treatment commencement,
serum OCN levels in Scl‐Ab–treated animals were still elevated
(p¼ 0.034) compared with the intact control group. Scl‐Ab
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increased serum P1NP levels 3 weeks after the start of treatment
compared with both intact (p¼ 0.10) and vehicle‐treated EP
(p¼ 0.058) groups (Fig. 5C), whereas there were no statistical
differences, in P1NP levels, detected between intact, vehicle‐
treated EP, and Scl‐Ab–treated EP groups at 6 weeks. In addition
to the increase in systemic bone‐formation biomarkers, Scl‐Ab
treatment exhibited no change on serum TRAP 5b levels
during the 6‐week therapeutic phase after ligature‐induced EP
(Fig. 5D).
Regeneration mode: detection of SOST in alveolar bone
tissues
Anabolic effects of Scl‐Ab on alveolar bone regeneration were
assessed at tissue level by histology. Hematoxylin and eosoin
(H&E) images of the tooth‐root encompassing bone conﬁrmed
the sustained bone loss after EP induction. Six weeks of Scl‐Ab
treatment restored the lost bone microarchitecture, volume, and
density to levels comparable to intact control (Fig. 6A–C).
Immunostainings for sclerostin and cathepsin K expression were
performed tomonitor the target protein and active osteoclasts at
the site of EP. After 6 weeks of Scl‐Ab therapy (Fig. 6D–F), IHC
revealed an increased presence of the protein sclerostin within
the lacunae, canaliculi, and marrow spaces of the alveolar bone
of maxillary M1 and M2 (Fig. 6F). In comparison, sclerostin was
minimally detected within the alveolar bone of both the intact
and vehicle‐treated EP control groups after 6 weeks (Fig. 6D, E).
IHC for cathepsin K was applied to detect the presence of active
osteoclasts at the site of EP; 6 weeks of Scl‐Ab therapy did
not lead to a change in osteoclast number and surface coverage
(Fig. 6G–I and data not shown) in the eroded interdental
regions of alveolar bone, which was consistent with unchanged
serum TRAP 5b concentrations with Scl‐Ab (Fig. 5C). Descriptive
analysis of a small subset of calcein‐labeled mandibular samples
revealed that Scl‐Ab increased bone apposition rate compared
with the vehicle‐treated EP and intact groups (Fig. 6J–L), as
demonstrated by the increased distance between ﬂuorescent
bands in the Scl‐Ab–treated EP group at 6 weeks.
Prevention mode
To examine whether Scl‐Ab could prevent alveolar bone loss in
maxillary bone affected by periodontal disease, Scl‐Ab was
injected concurrently with placement and during the continuous
Fig. 2. Scl‐Ab increases alveolar bone mass and serum bone formation markers in intact animals. (A) BVF and TMD of intact maxillary tooth‐supporting
alveolar bone at 2 and 4 weeks using micro‐CT scanning. (B) Femur bone mineral density (BMD) by DXA scanning at 4‐week time point. (C) Serum bone‐
biomarker analysis at 2 and 4 weeks after commencement of Scl‐Ab therapy.
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presence of ligatures. Systemic Scl‐Ab administration in the EP
group resulted in only nonsigniﬁcant, modest increases in both
BVF and TMD at 2‐ and 4‐week time points when compared with
corresponding vehicle controls (Supplemental Fig. S2A, B). This
result indicates that Scl‐Ab might be well suited as an adjunctive
therapy, in conjunction with aggressive management of
inﬂammation.
Discussion
Outcomes of sclerostin inhibition using a neutralizing monoclo-
nal antibody have been studied in clinical trials for postmeno-
pausal osteoporosis, and in preclinical models of osteoporosis,
osteogenesis imperfecta, rheumatoid arthritis, bone repair, and
fracture healing.(13–15,20–23) In both the preclinical and clinical
settings, administration of Scl‐Ab is consistently associated with
increased bone formation, bone mass, and bone density at
several sites throughout the body, but effects within the
craniofacial complex have never been investigated.
Our study provides early preclinical evidence that sclerostin
has an ongoing role in minimizing alveolar bone mass post‐
developmentally in young growing rats. Sclerosteosis patients
display increased jawbone growth because of the genetic
deﬁciency of sclerostin during early growth and development.
We now document that blockade of sclerostin via neutralizing
Scl‐Ab displays an anabolic effect on alveolar bone, both under
physiologic conditions and therapeutically after EP‐induced
bone loss. Within 2 weeks of subcutaneous Scl‐Ab administra-
tion, intact tooth‐supporting alveolar bone exhibited signiﬁcant-
ly greater bone volume fraction and mineral density relative to
vehicle control, and this effect was maintained through week 4.
Under active inﬂammatory conditions such as the prevention
study shown here, Scl‐Ab administration in EP groups had limited
effects on focal BVF and TMD when compared with correspond-
ing vehicle controls. Although Scl‐Ab has been shown to halt
systemic bone loss under inﬂammatory conditions in a mouse
model of chronic colitis,(24) speciﬁc interactions between Scl‐Ab
and inﬂammatory pathways in alveolar bone merit further
investigation. Furthermore, additional studies with longer
treatment durationwill be needed to determine the preventative
potential of Scl‐Ab under active periodontal inﬂammatory
conditions.
In healthy intact animals, the increases by Scl‐Ab in alveolar
bone volume and density corresponded with increased long
bone mass and density at 4 weeks. Furthermore, increases in
bone volume and density were consistent with a trend toward
increased serum OCN at 2 and 4 weeks and a signiﬁcant increase
in the bone formation marker P1NP at 4 weeks. Femur bone
density and serum bone formation markers in an aged, gonad‐
intact male rat model with the same treatment regimen showed
similar treatment response.(25) In general, Scl‐Ab has been shown
to either decrease or have no effect on serum TRAP 5b levels
across a variety of preclinical animal models.(25,26) In addition to
the bone anabolic response, Scl‐Ab also showed beneﬁcial anti‐
resorptive effect as evidenced by the decreased level of CTXI in a
recent clinical trial.(15)
Our ﬁndings also suggest that under the current experimental
conditions, Scl‐Ab administration reverses alveolar bone loss in a
preclinical animal model of periodontitis. After EP induction—
which resulted in decreases of 30% and 32% in BVF and TMD,
respectively—animal groups receiving Scl‐Ab exhibited higher
alveolar bone volume and density compared with vehicle
controls after just 3 weeks of therapy. Additionally, although
Fig. 3. Micro‐CT assessment of alveolar bone BVF, TMD, and ABL during
Scl‐Ab therapy after induction of experimental periodontitis. Change in
BVF (A) and TMD (B) throughout the regenerative study with
subcutaneous dosing. Three weeks after ligature removal, BVF and
TMD of vehicle‐treated EP and intact groups were still statistically
different (#p< 0.05 versus intact). After 6 weeks of Scl‐Ab treatment, BVF
and TMD showed no statistical differences compared with the intact
group (p< 0.05 versus Scl‐Ab). (C) Mean linear ABL around ﬁrst and
second maxillary molars measured using micro‐CT software. Scl‐Ab
treatment for 6 weeks led to a signiﬁcant recovery of disease‐induced ABL
compared with vehicle‐treated EP group (p< 0.05 versus Scl‐Ab;
#p< 0.05 versus intact; •p< 0.05 versus vehicle).
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Fig. 4. Sclerostin antibody facilitates alveolar bone regeneration after experimental periodontitis. Representative micro‐CT images of maxillary alveolar
bone surrounding the ﬁrst (M1) and second (M2) molars at (A) baseline and (B) 6‐week time points for intact and EP treatment groups. Representative
sagittal and transverse slices (2D) as well as 3D images ofmaxillary samples help showcase the visual differences between the amount of bone regenerated
around M1 and M2 in Scl‐Ab–treated animals versus vehicle‐treated animals after 6 weeks.
Fig. 5. Scl‐Ab increases serum concentration of bone formation markers osteocalcin and P1NP in regeneration study. Femur BMD (A) and serum
concentrations of OCN (B), P1NP (C), and TRAP 5b (D) at baseline, 3‐week, and 6‐week time points.
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natural healing of bone plateaued approximately 3 weeks after
ligature removal, BVF and TMD continued to increase with Scl‐Ab
treatment for up to 6 weeks. After 6 weeks of systemic Scl‐Ab
therapy, signiﬁcant increases in alveolar bone volume and
density were observed compared with the vehicle‐treated EP
group. Furthermore, no statistical difference was found between
alveolar bone BVF and TMD of EP compared with intact, healthy
animals.
The lack of effect of locally administered Scl‐Ab on alveolar
bone regeneration may be owing to the absence of special
carriers for maintaining high local drug exposure, and/or the
insufﬁcient amount of total Scl‐Ab administered via this route
(approximately 25‐fold lower than the systemic dose). More
sophisticated local delivery approaches with sustained con-
trolled release proﬁles may have therapeutic potential and
should be explored. The local anabolic bone response detected
in animals treated with systemic Scl‐Ab may have been owing in
part to the activation of downstream systemic modulators that
inﬂuence bone formation and remodeling. Recent studies
suggest that sclerostin affects bone metabolism by decreasing
concentrations of both vitamin D and PTH.(27,28) Therefore, a
systemic sclerostin blockade may prove more effective in
activating bone anabolic signaling pathways in addition to
Wnt signaling to a greater extent than what may be achieved
with local delivery.
Collectively, the current data suggest that systemic Scl‐Ab
administration results in a global skeletal anabolic effect and
active mineralization on the surface of both cortical and
trabecular bone in the jaws. Despite the positive outcomes of
systemic Scl‐Ab delivery on volumetric measures of alveolar
bone, the effects on linear bone height under the current
conditions were limited. The kinetics of linear ABL changes
associated with systemic Scl‐Ab administration suggest that
greater improvements might be found with longer‐term
treatment, a hypothesis that warrants further study. Nonetheless,
the overall alveolar bone responses to systemic Scl‐Ab
Fig. 6. Histological evaluation and IHC detection of bonemarkers in tooth‐supporting alveolar bone after 6weeks of Scl‐Ab administration in regeneration
study. ROI for H&E (A–C) and SOST IHC (D–F) marked as black dotted rectangular outline on sagittal section (2magniﬁcation) of M1/M2 and supporting
alveolar bone. Red, dotted rectangular outline marks ROI for CathK IHC (G–I). H&E sections (A–C) of alveolar bone surrounding the roots of M2 (20
magniﬁcation). (D–F) IHC staining for SOST (40magniﬁcation) indicated an increased presence of sclerostin protein in osteocytes and marrow spaces of
tooth‐supporting alveolar bone after Scl‐Ab treatment. Red triangles indicate SOST‐positive osteocytes and white triangles indicate SOST‐negative
osteocytes. (G–I) CathK IHC staining (10magniﬁcation) for osteoclast cells present on the surface (indicated by yellow triangles) of the interproximal bone
of M1 and M2. CathK‐positive cells (marked by asterisk) also present within the marrow spaces. (J–L) Calcein double‐labeling images of interradicular
alveolar bone from intact, vehicle‐treated EP, and Scl‐Ab–treated EP groups. Scl‐Ab treatment increases the mineral apposition rate in tooth‐supporting
alveolar bone as detected by ﬂuorescent calcein labeling (yellow‐outlined orange triangles).
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administration improved alveolar bone stock, which might result
in higher‐quality tooth‐supporting alveolar bone. Collectively,
the observed increases in alveolar BVF and TMD and the
decrease in ABL with systemic Scl‐Ab might serve to better
preserve at‐risk natural teeth in the periodontitis setting, and/or
to better prepare affected regions of bone for prosthetic
implants.
The presence of the sclerostin protein was dramatically
increased in the alveolar bone of animals treated with Scl‐Ab
compared with vehicle‐treated controls, which might reﬂect an
accumulation of the inactive, neutralized sclerostin protein
trapped within the tissues, and/or perhaps an increase in
intracellular sclerostin within osteocytes, suggesting a compen-
satory upregulation of sclerostin upon inhibition by Scl‐Ab. As
anticipated, sclerostin was localized to the osteocyte‐containing
lacunae, as well as throughout the connecting network of
canaliculi of the alveolar bone. Furthermore, sclerostin was also
detected on the bone surface of marrow spaces within alveolar
bone, suggesting that Scl‐Ab may facilitate bone formation by
enhancing differentiation of osteoblast precursors within the
bone marrow.(29)
Within a small subset of samples, ﬂuorescent calcein labeling
revealed an anabolic effect at both 3 and 6 weeks in groups
receiving Scl‐Ab therapy. Furthermore, the anabolic effects of
sclerostin neutralization on bone appear to be enhanced by
normal mechanical loading.(30) Increased regional alveolar bone
formation was observed on the mesial surfaces and bone
marrow spaces of the mandibular alveolar bone. Sclerostin has
been shown to be important in mechano‐sensation and the
preservation of alveolar bone mechanical properties in response
to the masticatory forces acting on the surface of bone.(29)
However, further investigation will be needed to determine the
relationship between natural forces and Scl‐Ab–mediated bone
apposition in alveolar bone.
The prolonged absence of sclerostin, during development and
throughout life, in patients suffering from sclerosteosis, leads to
several characteristic clinical features evident in their craniofacial
tissues. Patients display irregular dentition with dental maloc-
clusion, increased spacing between teeth, and excess cellular
cementum, which are believed to be secondary defects resulting
from loss‐of‐function of sclerostin.(31) Additionally, in rare cases,
partial anodontia and delayed eruption have also been
recorded.(32) A deeper understanding of the mechanisms behind
the clinical manifestations in patients with sclerosteosis and
SOST knockout animal models could provide insight into the
development of models for further studying the effects of
sclerostin deﬁciency on craniofacial tissues.
Several study limitations are worth mentioning. When the
regeneration study was terminated, improvements in ABL with
Scl‐Ab were only beginning to manifest. Because ABL can be an
important surrogate for clinical measures of PD, it will be
important to examine the reproducibility of this positive effect
and to test whether ABL further improves with longer durations
of Scl‐Ab administration. Themodest effects of Scl‐Ab on alveolar
bone in the prevention protocol, wherein active inﬂammation
and ligatures were present throughout, might suggest that Scl‐
Ab therapy would be more effective as an adjuvant to standards
of care that reduce active inﬂammation. It also remains unclear as
to whether Scl‐Ab might impact the periodontal ligament and
the strength of tooth attachment. Although sclerostin expression
has been localized in tooth‐associated cementocytes in rodents/
humans, the effects of sclerostin loss‐of‐function on cementum
tissue remain unclear,(33,34) and the role of sclerostin in
cementum homeostasis and formation, as well as the effects
of sclerostin neutralization on cementum regeneration, warrant
further investigation in the future. However, in this study, we
noted that along with alveolar bone regeneration, there was a
corresponding cementum that formed without signiﬁcant
alterations to the thickness or general morphology, similar to
intact cemental surfaces in health animals. Further studies would
be required to more carefully determine sclerostin’s role on
cementogenesis, especially in situations of complete cemental
removal after root‐planing procedures, not performed in this
study. Future studies will be required to monitor alveolar bone
levels after the cessation of Scl‐Ab therapy. Additionally, it will be
important to monitor the anabolic effects of systemic Scl‐Ab
delivery at different sites throughout the body to avoid
potentially detrimental effects of excess bone formation.
In summary, Scl‐Ab treatment induces an anabolic response in
alveolar bone under physiologic conditions, as well as during
alveolar bone healing in experimental periodontitis by increasing
bone formation. Our results support the rationale for the clinical
investigation of Scl‐Ab in augmenting alveolar bone healing and
facilitating bone regeneration in a dental setting for patients with
periodontal disease.
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